Bliss GVS Pharma has released its financial results for the second quarter, showcasing a mixed performance with revenue growth but declining profitability.

Financial Highlights

Bliss GVS Pharma reported a consolidated net profit of 0.27 billion rupees for the second quarter, marking a 12.35% increase from 0.24 billion rupees in the same period last year. The company's revenue also saw growth, rising to 2.40 billion rupees from 2.20 billion rupees year-over-year, representing a 9.09% increase.

Profitability Concerns

Despite the growth in revenue and net profit, the company faced challenges in maintaining its profitability levels:

• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined to 0.31 billion rupees from 0.42 billion rupees in the previous year, a significant drop of 25.78%.
• The EBITDA margin compressed to 12.58% from 19.06%, representing a decrease of 6.48 percentage points.

This decline in EBITDA and margin compression suggests that the company may be facing increased operational costs or pricing pressures in its market segments.

Management Changes

In related news, the company announced significant management changes in its recent board meeting:

1. Mr. Gagan Harsh Sharma has resigned from his position as Managing Director, effective November 6, 2025, citing other professional commitments.
2. Mr. Shreekrushna Joshi has been appointed as Head – Legal and Senior Management Personnel, bringing over 15 years of experience in corporate legal and secretarial compliance.

These management changes may impact the company's strategic direction and operational efficiency in the coming quarters.

Looking Ahead

While Bliss GVS Pharma has shown resilience in growing its revenue and net profit, the declining EBITDA and margin compression highlight challenges that the company needs to address. Investors and market analysts will be keenly watching how the new management tackles these issues and steers the company towards improved operational efficiency in the future quarters.

As the pharmaceutical sector continues to evolve, Bliss GVS Pharma's ability to maintain growth while improving profitability will be crucial for its long-term success in the competitive market landscape.

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has recently expanded its share capital through the allotment of equity shares under its Employee Stock Option Plan (ESOP). This move underscores the company's commitment to employee incentivization and aligns with its growth strategy.

Key Details of the Allotment

The ESOP Allotment Committee of Bliss GVS Pharma approved the issuance of 33,670 equity shares on November 5, 2025. These shares, each with a face value of Re. 1, were allotted to eligible employees who exercised their stock options under the company's Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).

Impact on Share Capital

Following this allotment, the company's share capital structure has undergone the following changes:

Financial and Regulatory Aspects

• Exercise Price: The shares were allotted at an exercise price of Rs. 43.00 per share, which includes a premium of Rs. 42.00 per share.
• Lock-in Period: The newly allotted shares are subject to a lock-in period of six months from the date of allotment, set to expire on May 5, 2026.
• Listing: The shares are expected to be listed on both the BSE Limited and the National Stock Exchange of India Limited, where the company's existing shares are traded.
• ISIN: The allotted shares carry the ISIN INE416D01022, consistent with the company's existing equity shares.

Regulatory Compliance

This allotment is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has duly informed the stock exchanges about this corporate action, adhering to the principles of transparency and regulatory disclosure.

Implications for Investors and Employees

For existing shareholders, this allotment represents a marginal dilution of 0.03% in their shareholding. However, it also signifies the company's focus on aligning employee interests with those of the shareholders, potentially driving long-term value creation.

For the employees who received these shares, it presents an opportunity to participate in the company's equity and benefit from its future growth, subject to the specified lock-in period.

As Bliss GVS Pharma continues to navigate the dynamic pharmaceutical landscape, this ESOP allotment serves as a testament to its strategy of fostering employee engagement and retention through equity participation.